杭州煌森生物科技

Huangsen Biotech is a biotechnology company based in Hangzhou, China, focused on the development of innovative protein degradation therapies. The company utilizes its proprietary Proteolysis Targeting Chimera (PROTAC) platform to design small molecules that recruit the body's natural protein disposal system to eliminate disease-causing proteins. Its primary research efforts are directed toward oncology, specifically targeting the Androgen Receptor for the treatment of advanced prostate cancer. Huangsen Biotech aims to address clinical challenges such as drug resistance by developing highly selective and potent degraders for previously undruggable targets.